Proflavine Hemisulfate

Research use only, not for human use.

Proflavine Hemisulfate is a topical antiseptic by interchelating DNA, thereby disrupting DNA synthesis and leading to high levels of mutation in the copied DNA strands.

Proflavine Hemisulfate is a topical antiseptic by interchelating DNA, thereby disrupting DNA synthesis and leading to high levels of mutation in the copied DNA strands.(In Vitro):Proflavine (0.1-10 μM; 24 hours) inhibits the growth of Kir3.2-transformant cells and Kir3.2 activity in a concentration-dependent manner.Proflavine (300 μM) progressively reduces the current amplitude of Kir3.2 mutant to 27.7±4.3% of the control.(In Vivo):Proflavine (0.1-10 μM; 24 hours) inhibits the growth of Kir3.2-transformant cells and Kir3.2 activity in a concentration-dependent manner.Proflavine (300 μM) progressively reduces the current amplitude of Kir3.2 mutant to 27.7±4.3% of the control.

Proflavine (0.1-10 μM; 24 hours) inhibits the growth of Kir3.2-transformant cells and Kir3.2 activity in a concentration-dependent manner. Proflavine (300 μM) progressively reduces the current amplitude of Kir3.2 mutant to 27.7±4.3% of the control. Cell Viability AssayCell Line:Kir3.2*-transformant BYT123 cells Concentration:0.1, 1, and 10 μM Incubation Time:24 hours Result:Dose-dependent inhibition of the growth of Kir3.2*-transformant cells. Attenuated the growth of Kir3.2*-transformant cells without affecting the growth of control cells.

The concentrations of Proflavine (20 mg/kg) in whole blood after intravenous injection decreased rapidly at the beginning and remained stable from around 30 min after dosing. Animal Model:Adult male Sprague Dawley rats (weighing approximately 200 g) Dosage:20 mg/kg (Pharmacokinetic Analysis) Administration:Intravenous injection; 2, 4, 5, 10, 15, 20, 25, and 30 min after dosing Result:Concentration decreased rapidly from whole blood in the first 5 min after dosing, followed by a slower decrease.

Proflavine hemisulfate | Proflavine hemisulphate | EINECS 217-320-3

Cell Cycle/DNA Damage

DNA/RNA Synthesis

DNA mutation| LfrR| QacR| Thrombin

Infection

——

1811-28-5

516.57

C26H24N604S

>98% (HPLC)

Water: 22 mg/mL (85.18 mM)

C1=CC(=CC2=NC3=C(C=CC(=C3)[NH3+])C=C21)N.C1=CC(=CC2=NC3=C(C=CC(=C3)[NH3+])C=C21)N.[O-]S(=O)(=O)[O-]

(6-aminoacridin-3-yl)azanium;sulfate

(-20℃)

With Ice Pack

≥ 2 years